Search clinical trials for: INSULIN GLARGINE (U300)

Total 4029 results

Sanofi

Completed

Single Dose Clamp Study To Compare Concentration/Time Profile And Metabolic Activity Profile Of 2 New Formulations Of Insulin Glargine With Lantus

Type 1 Diabetes Mellitus

Germany
Sanofi

Completed

A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes Mellitus

Type 1 Diabetes Mellitus

United States, Puerto Rico
Emory University

Completed

Glargine U300 Hospital Trial

Type 2 Diabetes

United States
Sanofi

Completed

Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Older Patients With Type2 Diabetes Insufficiently Controlled on Their Current Antidiabetic Medications (SENIOR)

Type 2 Diabetes Mellitus

United States, Australia, Spain, Korea, Republic of, Hungary, Mexico, Italy, Poland, Argentina, Canada, Colombia, France, Germany, Japan, Peru, Romania, Sweden, United Kingdom
Sanofi

Completed

Evaluation of the Efficacy and Safety of Insulin Glargine 300 U/mL in Patients With Type 2 Diabetes Mellitus Uncontrolled on Other Kinds of Insulin (ARTEMIS-DM)

Type 2 Diabetes Mellitus

Argentina, Colombia, Egypt, Hong Kong, India, Indonesia, Lebanon, Malaysia, Peru, Philippines, Saudi Arabia, South Africa, Thailand, Turkey
Sanofi

Terminated

Gla-300 and IDeg-100 in Insulin-Naïve People With Type 2 Diabetes Mellitus and Renal Impairment (TRENT)

Type 2 Diabetes Mellitus | Renal Impairment

United States, Czechia, Hungary, Poland, Serbia
Sanofi

Completed

Ease of Use and Safety of the New U300 Pen Injector in Insulin-Naïve Patients With T2DM

Diabetes Mellitus Type 2

Germany
Sanofi

Completed

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus (EDITION IV)

Type 1 Diabetes Mellitus

United States, Canada, Czech Republic, Denmark, Estonia, Finland, Hungary, Japan, Latvia, Netherlands, Puerto Rico, Romania, Sweden
Novo Nordisk A/S

Recruiting

A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)

Obesity | Diabetes Mellitus, Type 2

United States, Spain, Portugal, Italy, Greece, Romania, Slovakia, Czechia, South Africa, Ukraine
Sanofi

Completed

Study of Two Titration Algorithms With Insulin Glargine 300 Units/mL in Type 2 Diabetes Mellitus Patients (TITRATION)

Type 2 Diabetes Mellitus

Canada
Sanofi

Completed

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus on Basal Plus Mealtime Insulin

Type 1 Diabetes Mellitus

United States
Sanofi

Completed

A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to "Standard of Care" Basal Insulins in Insulin Naïve Patients Initiating Insulin (Reach-Control)

Diabetes Mellitus, Type 2

Germany, Spain, Brazil, France, Ireland, Romania, United Kingdom
Sanofi

Completed

A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to "Standard of Care" Basal Insulin in Patients Already Using Basal Insulin (REGAIN CONTROL)

Diabetes Mellitus, Type 2

Italy, Ireland, Spain, Greece, Finland, Romania, Brazil, United Kingdom, France, Switzerland
Indonesia University

Unknown

The Efficacy, Safety, and Immunogenicity Study Comparing an Insulin Glargine Biosimilar Sansulin Log-G to Lantus

Diabetes Mellitus

Indonesia
Sanofi

Completed

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin (EDITION I)

Type 2 Diabetes Mellitus

United States, South Africa, Canada, Czechia, Estonia, Finland, France, Germany, Hungary, Latvia, Mexico, Netherlands, Romania
Sanofi

Completed

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy (EDITION II)

Type 2 Diabetes Mellitus

United States, Finland, South Africa, Canada, Mexico, Chile, Spain, Russian Federation, France, Germany, Hungary, Portugal, Romania
Sanofi

Completed

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy (EDITION III)

Type 2 Diabetes Mellitus

United States, Bulgaria, Canada, Czech Republic, Denmark, Estonia, Finland, Hungary, Japan, Latvia, Lithuania, Netherlands, Puerto Rico, Romania, Slovakia, Sweden
Sanofi

Completed

Evaluation of Toujeo Insulin in Type 2 Diabetes Patients Inadequately Control With Their Basal Insulin Treatment (Transition II)

Diabetes Mellitus, Type 2

France
Sanofi

Completed

Phase 4 Study to Evaluate Treatment Optimization With Once-daily Insulin Glargine 300 U/mL (TOP1)

Type I Diabetes Mellitus

Brazil
Sanofi

Active, not recruiting

Evaluation of the Safety and Efficacy of Insulin Glargine 300 U/ml (Gla-300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus Uncontrolled on Oral Antihyperglycemic Drugs (SAFEGUARD)

Type 2 Diabetes Mellitus

India
Medanta, The Medicity, India

Completed

Degludec Glargine U300 Hospital Study

Type 2 Diabetes

India
University of Split, School of Medicine
Pavle Vrebalov Cindro; Jonatan Vuković; Darko Modun; Božo Smajić; Gordan Kardum; Tina... and other collaborators

Completed

Insulin Glargine U300 vs Insulin Degludec U100 in Impact on the Glycaemic and Cardiovascular Factors

Diabetes Mellitus, Type 2

Croatia
Sanofi

Completed

Comparison of Glucose Values and Variability Between TOUJEO and TRESIBA During Continuous Glucose Monitoring in Type 1 Diabetes Patients (inRange)

Type 1 Diabetes Mellitus

Turkey, Netherlands, Brazil, United States, Germany, Hungary, United Kingdom
Sanofi

Completed

Comparison of the Efficacy and Safety of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Insufficiently Controlled With Non-insulin Antidiabetic Therapy (EDITION AP)

Type 2 Diabetes Mellitus

China, Taiwan, Korea, Republic of
Sanofi

Completed

Comparison of MyStar DoseCoach to Routine Titration in Adult Patients With Type 2 Diabetes Mellitus Using Toujeo (AUTOMATIX)

Type 2 Diabetes Mellitus

Germany, United Kingdom
Novo Nordisk A/S

Completed

A Research Study of How Different Amounts of a New Medicine NNC0148-0287 C (Insulin 287) Works on the Blood Sugar of People Who Are Japanese With Type 1 Diabetes When Given Once a Week

Diabetes Mellitus, Type 1

Japan
Sanofi

Completed

Twelve -Month Study Observing How Insulin-naïve Patients With Type 2 Diabetes Mellitus Manage Diabetes Using Toujeo® After Oral Antidiabetic Drug Failure, the Side Effect of Toujeo®, and The Cost. (ATOS)

Diabetes

Peru, Ukraine, Colombia, Egypt, India, Indonesia, Israel, Jordan, Kuwait, Lebanon, Mexico, Philippines, Russian Federation, Saudi Arabia, Singapore, Taiwan, Thailand, United Arab Emirates
Eli Lilly and Company

Completed

A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections (QWINT-4)

Type 2 Diabetes | Type 2 Diabetes Treated With Insulin

United States, Germany, Mexico, Argentina, Puerto Rico, Italy, Spain, India
Novo Nordisk A/S

Completed

A Research Study in People With Type 2 Diabetes to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine

Diabetes Mellitus, Type 2

United States, Italy, Canada, Germany, Czechia
Sanofi

Terminated

LANTUSTITR: Insulin Glargine in Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Hungary
prof dr Pieter Gillard
University Hospital, Antwerp; Onze Lieve Vrouw Hospital

Completed

Evaluation of Glycemic Control and Quality of Life in Adults With Type 1 Diabetes During Continuous Glucose Monitoring When Switching to Insulin Glargine 300 U/mL (FUTURE-GLARE)

Type 1 Diabetes

Belgium
Novo Nordisk A/S

Completed

A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes (SUSTAIN 11)

Diabetes Mellitus, Type 2

Croatia, India, Poland, Spain, Serbia, Germany, Slovakia, Slovenia, Turkey, Hungary, Greece, Czechia, Bulgaria, South Africa, Romania, Bosnia and Herzegovina, Estonia, Portugal, Latvia, Lithuania, North Macedonia
Changhua Christian Hospital

Recruiting

Concurrent Subcutaneous Basal Insulin and Intravenous Insulin Pump in Hyperglycemic Crisis Patients Under Critical Care

Diabetic Ketoacidosis | Hyperglycaemic Crisis in Diabetes Mellitus | Hyperglycaemic Hyperosmolar Nonketotic Syndrome

Taiwan
Sanofi

Completed

Efficacy and Safety of LixiLan Versus Insulin Glargine Alone Both With Metformin in Japanese With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Drugs (LIXILAN JP-L)

Type 2 Diabetes Mellitus

Japan
Sanofi

Completed

Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Children and Adolescents With Type 1 Diabetes Mellitus (EDITION JUNIOR)

Type 1 Diabetes Mellitus

France, Czechia, Chile, Israel, Spain, Hungary, Mexico, Serbia, Japan, Canada, Brazil, Sweden, Denmark, Argentina, United States, Bulgaria, Germany, Italy, Latvia, North Macedonia, Poland, Romania, Russian Federation, United Kingdom
Novo Nordisk A/S

Completed

Comparison of Biphasic Insulin Aspart 70/30 Versus Insulin Glargine in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

United States, Puerto Rico
Sanofi

Completed

Insulin Glargine in Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2
Mira Zuidgeest
Sanofi; Innovative Medicines Initiative; IMI Trials@Home consortium

Recruiting

Remote And Decentralised Innovative Approaches to Clinical Trials (RADIAL) (RADIAL)

Diabetes Mellitus, Type 2

United Kingdom, Denmark, Germany
Sanofi

Completed

A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)

Diabetes Mellitus, Type 2

United States, Canada
Sanofi

Completed

A Clinical Efficacy and Safety Study of Insulin Glargine U300 in Chinese Adult Patients With Uncontrolled Type 2 Diabetes Mellitus With a 3-month Extension Period (INITIATION)

Type 2 Diabetes Mellitus

China
Sanofi

Completed

Efficacy and Safety of Toujeo® Versus Tresiba® in Insulin-Naive Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor Agonist (BRIGHT)

Diabetes Mellitus, Type 2

Israel, Czechia, Greece, Italy, United States, Bulgaria, Croatia, Denmark, France, Hungary, Romania, Serbia, Slovakia, Sweden, Switzerland, United Kingdom
Novo Nordisk A/S

Completed

Comparison of Insulin Glargine Versus Biphasic Insulin Aspart 30/70 or Biphasic Insulin Aspart 30/70 in Combination With Metformin in Subjects With Type 2 Diabetes.

Diabetes Mellitus, Type 2 | Diabetes

Turkey
Novo Nordisk A/S

Completed

Biphasic Insulin Aspart 30 in Type 2 Diabetes Failing OAD Therapy (INITIATE)

Diabetes Mellitus, Type 2 | Diabetes

United States
University of Jordan

Completed

Dosage Reduction and Acute Glycemic Complications in People With Type 2 Diabetes Who Fast During Ramadan

Diabetes Mellitus, Type 2

Jordan
Sanofi

Completed

Comparison of SAR341402 to NovoLog in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine (GEMELLI X)

Type 1 Diabetes Mellitus

United States
Weill Cornell Medical College in Qatar
Novo Nordisk A/S

Terminated

Randomised Open Label Study of Insulin Degludec Versus Insulin Glargine U100 in Ramadan

Type2 Diabetes

Qatar
Novo Nordisk A/S

Completed

A Research Study to Compare a New Weekly Insulin, Insulin Icodec Used With DoseGuide App, and Daily Insulins in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 5)

Diabetes Mellitus, Type 2

United States, Poland, Puerto Rico, Canada, Hungary, Germany, Turkey, Greece
IRCCS San Raffaele

Terminated

Normalization of Fasting Glucose and the Incidence of Restenosis After Peripheral Angioplasty (LIMBISCH)

Type 2 Diabetes Mellitus | Peripheral Vascular Disease

Italy
Novo Nordisk A/S

Completed

Comparison of Pharmacodynamics and Pharmacokinetics of Biphasic Insulin Aspart 30 and Insulin Glargine and Insulin Glulisine Therapy in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Germany
Novo Nordisk A/S

Completed

A Clinical Study to Compare the Efficacy and Safety of a Novel Medicine (NNC0268-0965) With Insulin Glargine

Diabetes Mellitus, Type 2

Germany

3

Subscribe